Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 222

1.

Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery.

Di Luzio R, Dusi R, Mazzotti A, Petroni ML, Marchesini G, Bianchi G.

Diabetes Metab Syndr Obes. 2020 Jan 7;13:9-17. doi: 10.2147/DMSO.S225796. eCollection 2020.

2.

Lifestyle changes for the treatment of nonalcoholic fatty liver disease - A 2015-19 update.

Petroni ML, Brodosi L, Barbanti FA, di Domizio S, Petta S, Marchesini G.

Curr Pharm Des. 2020 Feb 3. doi: 10.2174/1381612826666200204095401. [Epub ahead of print]

PMID:
32013841
3.

Fatty liver in pregnancy: a narrative review of two distinct conditions.

Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML.

Expert Rev Gastroenterol Hepatol. 2020 Jan 20:1-9. doi: 10.1080/17474124.2020.1715210. [Epub ahead of print]

PMID:
31928239
4.

Old subjects with sepsis in the emergency department: trend analysis of case fatality rate.

Fabbri A, Marchesini G, Benazzi B, Morelli A, Montesi D, Bini C, Rizzo SG.

BMC Geriatr. 2019 Dec 23;19(1):372. doi: 10.1186/s12877-019-1384-8.

5.

Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?

Petroni ML, Brodosi L, Marchignoli F, Musio A, Marchesini G.

Nutrients. 2019 Dec 13;11(12). pii: E3048. doi: 10.3390/nu11123048. Review.

6.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.

PMID:
31813633
7.

Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution.

Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E.

Acta Diabetol. 2020 Jan;57(1):115-116. doi: 10.1007/s00592-019-01441-3. Epub 2019 Nov 6. No abstract available.

PMID:
31691870
8.

Searching food during the night: the role of video-polysomnography in the characterization of the night eating syndrome.

Loddo G, Zanardi M, Caletti MT, Mignani F, Petroni ML, Chiaro G, Marchesini G, Provini F.

Sleep Med. 2019 Dec;64:85-91. doi: 10.1016/j.sleep.2019.06.018. Epub 2019 Jul 5.

PMID:
31671328
9.

Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study.

Petroni ML, Montesi L, Colosimo S, Caletti MT, Mazzotti A, Marchesini G.

Endocrinol Diabetes Metab. 2019 Jul 26;2(4):e00082. doi: 10.1002/edm2.82. eCollection 2019 Oct.

10.

Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?

Marchesini G, Petroni ML, Cortez-Pinto H.

J Hepatol. 2019 Dec;71(6):1073-1075. doi: 10.1016/j.jhep.2019.09.020. Epub 2019 Oct 3. No abstract available.

PMID:
31586595
11.

Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution.

Ponti F, Plazzi A, Guglielmi G, Marchesini G, Bazzocchi A.

BJR Case Rep. 2019 Mar 14;5(3):20170078. doi: 10.1259/bjrcr.20170078. eCollection 2019 Sep.

12.

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.

Lazarus JV, Ekstedt M, Marchesini G, Mullen J, Novak K, Pericàs JM, Roel E, Romero-Gómez M, Ratziu V, Tacke F, Cortez-Pinto H, Anstee QM; EASL International Liver Foundation NAFLD Policy Review Collaborators.

J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.

13.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.

Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M.

Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

PMID:
31442319
14.

Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V, Barcellona MR, Boemi R, Enea M, Giannetti A, Spatola F, Marchesini G, Craxì A, Petta S.

Clin Gastroenterol Hepatol. 2019 Aug 13. pii: S1542-3565(19)30886-9. doi: 10.1016/j.cgh.2019.08.011. [Epub ahead of print]

PMID:
31419571
15.

Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations.

Petroni ML, Barbanti FA, Bonadonna R, Bruno G, Caletti MT, Croci M, D'Eusebio C, Dei Cas A, Invitti C, Merlo F, Molteni A, Pontiroli A, Trento M, Veronelli A, Vigili de Kreutzenberg S, Marchesini G.

Nutr Metab Cardiovasc Dis. 2019 Sep;29(9):983-990. doi: 10.1016/j.numecd.2019.06.006. Epub 2019 Jun 19.

PMID:
31353206
16.

Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'.

Armstrong MJ, Marchesini G.

J Hepatol. 2019 Aug;71(2):246-248. doi: 10.1016/j.jhep.2019.05.010. Epub 2019 Jun 20. No abstract available.

PMID:
31229270
17.

Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes.

Reginato E, Pippi R, Aiello C, Sbroma Tomaro E, Ranucci C, Buratta L, Bini V, Marchesini G, De Feo P, Fanelli C.

J Clin Med. 2019 Jun 14;8(6). pii: E851. doi: 10.3390/jcm8060851.

18.

Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.

Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E.

Acta Diabetol. 2020 Jan;57(1):71-80. doi: 10.1007/s00592-019-01378-7. Epub 2019 Jun 15.

PMID:
31203438
19.

Prevention and Treatment of Sarcopenic Obesity in Women.

Petroni ML, Caletti MT, Dalle Grave R, Bazzocchi A, Aparisi Gómez MP, Marchesini G.

Nutrients. 2019 Jun 8;11(6). pii: E1302. doi: 10.3390/nu11061302. Review.

20.

Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

Raschi E, Poluzzi E, Marchesini G, De Ponti F.

Expert Opin Pharmacother. 2019 Jun;20(9):1087-1090. doi: 10.1080/14656566.2019.1598970. Epub 2019 Mar 28.

PMID:
30920851

Supplemental Content

Loading ...
Support Center